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who were transplanted at our facility between 2001 and 2005. 30
patients were placed on a thalidomide maintenance program.
Patients received various cytoreductive regimens prior to stem-
cell collection. 27 patients who received thalidomide were in
partial remission prior to ASCT; 3 patients were in complete
remission and none were refractory. Of the 38 patients who did
not receive maintenance 35 were in partial remission, 2 were in
complete remission and 1 was refractory. All patients except 2
received a preparative regimen including melphalan 200 mg per
meter squared. 24 patients received thalidomide maintenance
with 100 mg daily and 6 patients received 50 mg daily. The dose
given depended on prior tolerability of the drug and history.
Thalidomide was started between 120 and 150 days post ASCT.
Patients needed to have an ANC above 1000 and platelets above
100 as well as resolution of transplant related toxicities. 13
patients needed a decrease in thalidomide because of neuropa-
thy. One of these 13 patients also suffered from decreased GI
motility and bezoar.
The average time to progression was 32.5 months in the thalid-
omide group and 19 months in the patients who did not receive the
drug. Patients who received thalidomide after transplant had im-
proved median time to progression (36 months) compared to
patients who did not receive thalidomide (15 months). Low dose
thalidomide maintenance in combination with bisphosphonates
seemed to improve progression free survival in myeloma patients
after stem cell transplantation.
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COMPARISON OF MULTIPLE MYELOMA PATIENTS TREATED WITH AU-
TOLOGOUS STEM CELL TRANSPLANT HAVING RECEIVED THAL DEX OR
VAD
Beveridge, C.A.1, Orloff, G.J.1, Sheridan, M.J.2, Shelton, M.V.1 1Fair-
fax Northern Virginia Hematology-Oncology, PC, Fairfax, VA; 2Inova
Fairfax Hospital, Falls Church, VA.
Background and Rationale
Thalidomide Dexamethasone (Thal Dex) is one of the standard
preparation treatments for auto-transplant in patients with Multi-
ple Myeloma (MM). We evaluated 49 patients with MM to deter-
mine whether outcomes differed between those receiving Thal Dex
and those receiving Vincristine, Doxorubicin, and Dexamethasone
(VAD).
Materials and Methods
A retrospective assessment was performed of MM patients who
were transplanted at Inova Fairfax Hospital from 1997-2005. All
patients received either VAD or Thal Dex as primary therapy and
in preparation for auto-transplant. All patients had Karnofsky per-
formance scores of 80% and all were apheresed using a high
volume technique and ideal body weight for calculations with
G-CSF (G) or GGM-CSF, with goal of 5106/kg CD34 cells. All
patients were given 200 mg/m2 of Melphalan (MEL) over two days
and were treated with growth factor support G beginning day 4
though ANC recovery of 1000. Blood product replacement was
standardized to transfuse for hemoglobin 8 gm/dl or platelet
counts of 10,000/mm3. Viability was performed using ﬂow cy-
tometry and propidium iodide. Continuous variables were analyzed
as means and 95% conﬁdence intervals, but p-values were pro-
duced using a Wilcoxon Rank Sum Test for non-normally distrib-
uted data. Categorical variables were analyzed using a Fisher’s
Exact Test.
Discussion
In MM patients with comparable pretransplant performance sta-
tus being equal, there were no statistical differences in CD34 yield,
cell viability, days of apheresis, platelet transfusions, engraftment,
complications, or mobilization regimen between those receiving
VAD and those receiving Thal Dex. However, patients receiving
Thal Dex appeared to require more RBC blood product support
(p0.03).
Results
Variables/Drug
Group Thal Dex (N11) VAD (N38) p-value
Age (years) 59.8 {53.6, 66.0} 56.5 {52.9, 60.2} 0.38
Days of
apheresis 2.18 {1.46, 2.91} 2.00 {1.68, 2.32} 0.60
CD 34 yield 7.95 {4.05, 11.8} 7.82 {6.34, 9.30} 0.74
Viability Day 1 84.3 {76.8, 91.8} 80.6 {73.2, 88.0} 0.63
Viability Day 2 85.0 {78.3, 91.7} 90.8 {88.1, 93.5} 0.06
Viability Day 3 82.4 {71.8, 93.0} 84.0 {74.7, 93.3} 0.83
Days to ANC
Engraftment 14.1 {13.3, 14.9} 13.7 {13.1, 14.2} 0.36
Days to PLT
Engraftment 18.5 {15.9, 21.2} 19.8 {17.3, 22.3} 0.82
Number of PLT
Transfusions 3.91 {1.61, 6.21} 3.74 {2.61, 4.87} 0.84
Number of RBC
Transfusions 4.54 {3.00, 6.09} 3.00 {2.39, 3.61} 0.03
Mobilization
Regimen (%G) 100 76 0.10
Death <100
days 0 0 1.00
Mucositis II-IV
<30 days 25 13.5 0.36
Sepsis <30 days 16.7 2.7 0.12
Pneumonia <30
days 8.3 2.7 0.40
Karnofsky Score 95.83 94.48 1.00
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Background: The recommended treatment for younger patients
(pts) with newly diagnosed symptomatic MM is ASCT after some
form of cytoreductive therapy. One of the goals of the cytoreductive
therapy is to reduce the tumor bulk, in particular, decrease the plasma
cell bone marrow (BM) inﬁltration to less than 10-30% prior to stem
cell collection. However, the utility of this approach is controversial.
Objective: To evaluate the impact of the degree of plasma cell bone
marrow (BM) inﬁltration on mobilization kinetic and transplant out-
comes. Method: We conducted a retrospective study on all pts with
MM who underwent ASCT at our institution between 1/99 and
12/03. Stem Cell mobilization regimen consisted of the combination
of Cyclophosphomide 1.5-3g/m2, GM-CSF (5mcg/kg) starting on
Day #3 and G-CSF (5mcg/kg) on Day#7 until targeted CD 34 count
achieved. The median age at ASCT was 55 (range 41-73). All pts
received melphalan 200mg/m2 as conditioning regimen. The pts were
grouped according to degree of plasma cell inﬁltration on BM biopsy
performed beforemobilization. Group 1 had plasma cell inﬁltration of
10% (n26), group 2 had 10-29% involvement (n27) and group
3 had 30% plasma cell inﬁltration (n16). Results: Sixty-nine
patients were included in the study; 43 were rapid mobilizers (4
106 CD34 cells/Kg in one single collection), 7 slow mobilizers
(1.5  106 CD34 cells/kg over 4 collections or more) and 19
normal mobilizers (all other patients). The median days of apheresis
was 1 (range 1-6). Ordinal logistic regression model identiﬁed that for
each 10 point (10%) increase in plasma cell BM inﬁltration prior to
mobilization, it is 1.27 times more likely to be in the next slower
mobilization group (p value 0.0449). Age did not inﬂuence the
mobilization kinetic. The median progression-free survival and over-
all survival for the entire cohort were 28.5 and 45months respectively.
There was no relationship found between plasma cell involvement
Poster Session I54
prior to mobilization and progression free survival as well as overall
survival. Conclusion:We conclude that 1) degree of plasma cell BM
inﬁltration before mobilization did not predict for transplant out-
comes and 2) increased plasma cell BM inﬁltration before mobiliza-
tion adversely affect the efﬁciency of stem cell mobilization. Thus,
pre-transplant cytoreductive therapy improves stem cell collection
efﬁciency but did not affect the transplant outcomes.
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ID/KLH ACTIVE IMMUNOTHERAPY (FAVID) FOLLOWING HIGH DOSE
THERAPY (HDT) AND AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT) FOR NON-HODGKIN’S LYMPHOMA (NHL)
Holman, P.P.1, deMagalhaes-Silverman, M.2, Corringham, S.1,
Castro, J.E.1, Carrier, E.1, Lane, T.1, Gold, D.3, Ball, E.1 1Moores
UCSD Cancer Center, Blood and Marrow Transplantation Division, La
Jolla, CA; 2University of Iowa, Iowa City, IA; 3Favrille, Inc, San Diego,
CA.
Sixteen patients with NHL were treated in a pilot study evalu-
ating the feasibility, safety and potential efﬁcacy of patient speciﬁc
idiotype immunization (Id/KLH Active Immunotherapy) follow-
ing HDT and ASCT. FavId was administered along with GM-
CSF. Two patients continue in active treatment; 1 mantle cell
lymphoma (MCL) and 1 transformed NHL (TL) and are not
reported here. Of the remaining 14 patients, 8 had MCL, 4 had
follicular lymphoma (FL), 1 had small lymphocytic lymphoma
(SLL) and 1 had TL. The median number of prior regimens for all
patients was 3 (range 1-10). For MCL patients, the median number
of prior regimens was 2.5 (range 1-4) which included CHOP and
hyperCVAD /- rituximab (R). FL patients received a variety of
regimens including ﬂudarabine, CVP, CHOP, R alone or in com-
bination and Zevalin. All MCL and FL patients received HDT
with BEAM except 1 who received CEB. The TL patient received
Bexxar, Cy/VP-16. Idiotype immunizations were begun 3 months
following HDT/ASCT. Of the 6 patients with MCL who achieved
a CR following transplant, 5 remain in continuing CR (CCR)
between 27 and 60 months post-transplant. The 6th patient re-
lapsed after 40 months. Of the 3 patients with FL who obtained a
CR, 2 continue in CR at 41-58 months post-transplant. The 3rd FL
patient died from MDS at 34 months. Of the 5 MCL patients with
a continuing CR, 4 developed cellular anti-Id and anti-KLH re-
sponses and one was not tested. The patient who relapsed after 40
months also had both anti-Id and anti-KLH cellular responses. Of
the 3 FL patients who obtained a durable CR, 2 developed anti-Id
and anti-KLH cellular responses and the 3rd was not tested. Id/
KLH Active Immunotherapy was well tolerated with injection site
reactions being the most commonly reported adverse effects. GM-
CSF related myalgias were also commonly reported. We conclude
that Id/KLH Active Immunotherapy following HDT and ASCT
for MCL and FL is feasible, safe, associated with idiotype speciﬁc
immune responses and may be associated with prolonged remis-
sions, even in patients heavily pretreated with very immunosup-
pressive regimens.
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USE OF A NOVEL ORGANIC ARSENIC (ZIO-101) AFTER AUTOTRANS-
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Boise, L.H.6, Schwartz, B.7, Gale, R.P.7, Berenson, J.P.5 1Cleveland
Cancer Center, Cleveland, OH; 2Cross Cancer Institute, Edmonton, AB,
Canada; 3Center for Cancer and Blood Disorders, Bethesda, MD; 4My-
eloma Institute for Research and Therapy, Little Rock, AR; 5Institute for
Myeloma and Bone Cancer Research, West Hollywood, CA; 6University
of Miami School of Medicine, Miami, FL; 7ZIOPHARM Oncology, Inc.,
Charlestown, MA.
Background Autotransplants are commonly used to treat mul-
tiple myeloma; unfortunately most recipients relapse. Subsequent
therapy is often difﬁcult because of limited bone marrow reserve.
ZIO-101, a new organic arsenic, is active against human myeloma
cell lines in vitro and in scid mice with human myeloma xenografts.
ZIO-101 is active in phase-1 trials in multiple myeloma and has
little bone marrow toxicity. Because of these features, ZIO-101 is
a good candidate for therapy of multiple myeloma after an auto-
transplant.
Method Phase-1 and -2 trials in persons with multiple myeloma.
Pharmacokinetic (PK) studies.
Subjects N13. Median age, 57 y (range, 41-78 y); 5 were male.
All had advanced myeloma: median N prior therapies, 6 (range,
2-12). 6 received 1 prior autotransplants.
Dosimetry 4 cohorts received 25 courses of ZIO-101 with a
starting dose of 78 mg/me2/d IV and a maximum administered
dose (MAD) of 420 mg/me2/d. 2 schedules were studied: (1) daily
for 5 consecutive d every 4 w; and (2) twice weekly for 3 w every
4 w. Median N cycles was 2 (range, 1-10). Adverse events at doses
 300 mg/me2/d were modest and there was no clinically-impor-
tant bone marrow toxicity or QTc-prolongation. Estimated max-
imum tolerated dose (MTD) is 300-420 mg/me2/d.
Activity Activity was seen including subjects receiving a prior
autotransplant. Details will be presented.
PK Studies at 420 mg/me2/d showed a tmax  1 h (SD  0.9),
Cmax  1.06 g/mL (SD  0.07 g/mL), t1/2  17.8 h (SD 
1.4 h) and AUC0-  25.9 g  h/mL (SD  0.8 g  h/mL).
Conclusions ZIO-101 is safe in persons with multiple myeloma
at doses 300-420 mg/me2/d (MTD) and may be especially useful
posttransplant because of modest bone marrow suppression.
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(MCL) IN FIRST REMISSION (CR1) AFTER HEMATOPOIETIC STEM CELL
TRANSPLANTATION
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Introduction: MCL, accounts for 5% of non-Hodgkin lym-
phoma and is characterized by t(11;14) translocation leading to
Cyclin D1 over expression. It is currently considered incurable,
with a median overall survival (OS) of 3 to 4 years from diagnosis.
Results of hematopoietic stem cell transplant (HSCT) are mixed,
with earlier studies showing no survival advantage over conven-
tional chemotherapy, but more recent studies, suggesting better
outcome. The optimal timing of HSCT for patients (pts) with
MCL is not known.
Methods: Between 2/1994 and 5/2006, 70 consecutive pts with
MCL underwent an autologous (auto) (n  56) or allogeneic (allo)
[n  14 (11-myeloablative; 3-reduced intensity regimens-RIC)].
Most pts had stage IV disease 50/70 (71%). 46/70 (66%) pts had
bone marrow (BM) involvement. Conditioning regimen for auto
HSCT consisted mainly of CBV (cyclophosphamide, BCNU and
etoposide). Allo HSCT regimens included ablative (cyclophosph-
amide/VP16  TBI); or RIC (ﬂudarabine/busulfan or ﬂudarabine/
TBI). GVHD prophylaxis consisted of cyclosporine (CSA) and
methotrexate or CSA/mycophenolate mofetil. 56 pts received BM,
10-peripheral blood (PB) and 4 (BM/PB).
Results: Median age at transplant was 56 years (yrs) (range
35-67). Median follow up was 2.1 yrs (range, 0.01-9.1). 50% of the
pts had at least 2 prior therapies prior to transplant. 55/70 pts had
a response after transplant (52-complete remission, and 3 partial
responses). 4/70 pts had no response and progressed. 35 pts are
alive (27-autologous; 8-allogeneic), of which 17 pts relapsed. 35
patients are dead: progressive disease, 23; sepsis/infection, 5; sec-
ondary malignancy, 2; pulmonary embolism, 1; and other causes, 4.
Median OS was 3.5 yrs (95% CI 2.4 to 4.6) with no signiﬁcant
difference between auto and allo (median not reached) pts (P 
0.78). Median progression free survival (PFS) was 3.5 yrs (95% CI
0.6 to 6.3), and was not different for auto or allo (median not
reached) HSCT (P0.82). 25/70 (36%) patients underwent
HSCT (auto-24, allo-1) in CR1. OS of these patients was superior
compared to pts transplanted later in their disease course (not
reached vs. 2.5 yrs, P0.023).
Conclusion: Patients transplanted in CR1 have a better overall
survival compared to being transplanted later in the disease course.
Pts not achieving CR1 or presenting with recurrence of disease
should be considered for early transplant. The optimal type of
transplant in these patients needs to be further validated.
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